文献速递新发突发、热带与寄生虫病

他非诺喹对恶性疟原虫血液阶段攻击的预防效果与安全性:随机双盲安慰剂对照1b期试验

Blood Schizonticidal Activity and Safety of Tafenoquine When Administered as Chemoprophylaxis to Healthy, Nonimmune Participants Followed by Blood Stage Plasmodium falciparum Challenge: A Randomized, Double-blind, Placebo-controlled Phase 1b Study.
PubMed 文献 · Clin Infect Dis · 2019-01-01

该随机双盲安慰剂对照1b期试验纳入16名无疟疾免疫力且G6PD正常的健康参与者,在血液阶段恶性疟原虫攻击前给予他非诺喹或安慰剂预防。

要点

  • 他非诺喹预防可完全阻止血液阶段恶性疟原虫攻击后的寄生虫血症。
  • 他非诺喹组不良反应轻微,包括轻度血红蛋白下降和高胆红素血症。
  • 该研究为小样本1b期试验,需更大规模研究验证。

核心结论

  • 他非诺喹化学预防在健康无免疫力参与者中预防血液阶段恶性疟原虫攻击所致疟疾安全有效。

研究设计与样本

  • 随机、双盲、安慰剂对照1b期研究,纳入16名20-42岁无疟疾且G6PD正常的参与者,他非诺喹组12例、安慰剂组4例。
  • 参与者在第1、2、3和10天接受单次200 mg盲法研究药物,第13天静脉接种约2800个恶性疟原虫感染红细胞。

主要发现

  • 他非诺喹组发生2例轻度血红蛋白下降和1例轻度高胆红素血症。

关键数值与推荐

  • 主要终点为因定量PCR确定出现寄生虫血症而需接受蒿甲醚/苯芴醇救援治疗的参与者数量。

临床怎么用

  • 他非诺喹可作为疟疾化学预防的候选药物,用于无免疫力人群预防血液阶段感染。

局限性

  • 样本量小(仅16例),需更大规模研究进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Tafenoquine was recently approved for chemoprophylaxis of malaria. Its specific activity against liver and blood stages of Plasmodium species has been separately characterized in animals but not in humans. METHODS: In this randomized, double-blind, placebo-controlled study, 16 malaria-naive, glucose-6-phosphate dehydrogenase-normal participants aged 20-42 years received tafenoquine chemoprophylaxis prior to challenge with blood stage Plasmodium falciparum. Participants were randomly assigned to either tafenoquine (n = 12) or placebo (n = 4) and took blinded study medication (single 200-mg dose) on days 1, 2, 3, and 10, followed by intravenous inoculation with approximately 2800 P. falciparum parasitized erythrocytes on day 13. The primary endpoint was the number of participants requiring rescue treatment with artemether/lumefantrine due to the onset of parasitemia as determined by quantitative polymerase chain reaction. RESULTS: None of the 12 participants who received tafenoquine developed parasitemia, whereas all placebo participants developed parasitemia (P = .0005). Two cases of mild hemoglobin decrease and a single case of mild hyperbilirubinemia occurred in the tafenoquine group. CONCLUSIONS: Tafenoquine chemoprophylaxis is safe and effective in preventing malaria in healthy nonimmune participants challenged with blood stage P. falciparum. CLINICAL TRIALS REGISTRATION: Australian and New Zealand Clinical Trials Registry (ANZCTR): ACTRN12617000102370.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. McCarthy JS, Smith B, Reid M, et al. Blood Schizonticidal Activity and Safety of Tafenoquine When Administered as Chemoprophylaxis to Healthy, Nonimmune Participants Followed by Blood Stage Plasmodium falciparum Challenge: A Randomized, Double-blind, Placebo-controlled Phase 1b Study. Clin Infect Dis. 2019. PMID: 30388194. doi:10.1093/cid/ciy939

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。